<SEC-DOCUMENT>0001193125-15-292742.txt : 20150817
<SEC-HEADER>0001193125-15-292742.hdr.sgml : 20150817
<ACCEPTANCE-DATETIME>20150817100058
ACCESSION NUMBER:		0001193125-15-292742
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20150814
FILED AS OF DATE:		20150817
DATE AS OF CHANGE:		20150817

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Prima BioMed Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		151057986

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 7, 151 MACQUARIE STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d22493d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13A-16</FONT> OR
<FONT STYLE="white-space:nowrap">15D-16</FONT> UNDER THE </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated August 14, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">001-35428</FONT> </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>RIMA</SMALL> B<SMALL>IO</SMALL>M<SMALL>ED</SMALL> L<SMALL>TD</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of Registrant&#146;s Name) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 7, 151 Macquarie Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by
check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT STYLE="white-space:nowrap">40-F.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
<FONT STYLE="white-space:nowrap">20-F&nbsp;&nbsp;</FONT><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;</FONT><FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (1):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by
Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b) (7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;
&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b): Not applicable. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: August 17, 2015 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="80%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><B>Prima BioMed Ltd</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:25.30pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:75.45pt; font-size:8pt; font-family:Times New Roman"><B>Description of Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><B>Prima BioMed Announces Commencement of Milestones for IMP701 Program</B></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d22493dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g22493g22k04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14&nbsp;August 2015 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PRIMA BIOMED ANNOUNCES
COMMENCEMENT OF MILESTONES FOR IMP701 PROGRAM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA&#151;Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (&#147;Prima&#148; or the
&#147;Company&#148;) today announced it will receive an undisclosed clinical milestone payment from its collaboration and licensing agreement with Novartis relating to its Phase I IMP701 LAG-3 antibody. The antibody is being trialled for the
treatment of cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep (which Prima Biomed acquired in December 2014) and CoStim Pharmaceuticals (which Novartis acquired in February 2014) entered
into a commercial licensing and collaboration agreement in September 2012, under which CoStim obtained a licence to develop and commercialise antagonistic LAG-3 antibodies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novartis has full responsibility for the continued development of the antibody program and Prima is eligible to receive further potential development-based
milestone payments and royalties on sales following commercialisation of the products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Marc Voigt, CEO of Prima, commented &#147;There is strong
preclinical evidence that antibodies to LAG-3 can promote an increased and sustained anti-cancer immune response. We are delighted that Novartis has now moved that concept into the clinic with help from our work in the field.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP701 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP701 is a therapeutic antibody originally
developed by Immutep to target LAG-3. This antagonist antibody plays a role in controlling the signalling pathways in both effector T cells and regulatory T cells (Treg). The antibody works to both activate effector T cells (by blocking inhibitory
signals that would otherwise switch them off) and at the same time inhibit Treg function that normally prevent T cells from responding to antigen stimulation. The antibody therefore removes two brakes that prevent the immune system from responding
to and killing cancer cells. In contrast, some other checkpoint antibodies in development target only the effector T&nbsp;cell pathway and don&#146;t address the Treg pathway. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Prima BioMed </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is a globally active
biotechnology company that is striving to become a leader in the development of immunotherapeutic products for the treatment of cancer. Prima BioMed is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed
Ltd</B>, Level 7, 151 Macquarie Street, Sydney NSW 2000<B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224 Fax: +61 2 8259 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima&#146;s original product, called CVac, is an <I>ex vivo</I> dendritic cell priming therapy that in May 2015 yielded favourable Phase II data in second
remission ovarian cancer patients. Prima is currently seeking partners for further development of this therapy. Prima&#146;s current lead product is IMP321, based on the LAG-3 immune control mechanism which plays a vital role in the regulation of
the T cell immune response. IMP321, which is soluble LAG-3, is a T cell immunostimulatory factor for cancer chemoimmunotherapy which has completed early Phase II trials. A number of additional LAG-3 products including antibodies for immune response
modulation in autoimmunity and cancer are being developed by large pharmaceutical partners.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prima BioMed is listed on the Australian Stock Exchange and on
the NASDAQ in the US. For further information please visit <U>www.primabiomed.com.au.</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prima BioMed Ltd: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stuart Roberts </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;447 247 909; <U>stuart.roberts@primabiomed.com.au</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australia Investor/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Mr Matthew Gregorowski,
Citadel Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)&nbsp;422 534 755; mgregorowski@citadelpr.com.au </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Prima BioMed
Ltd</B>, Level 7, 151 Macquarie Street, Sydney NSW 2000<B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Phone: +61 2 9276 1224 Fax: +61 2 8259 1880 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">www.primabiomed.com.au ABN: 90 009 237 889 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g22493g22k04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22493g22k04.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M 2(  A$! Q$!_\0 'P   04! 0$! 0$           $" P0%!@<("0H+_\0
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M[O%? 5;(Z"Q,:OM*=[/2S7^9]$6-]#>6T<]M+%-#.-\4D3!ED4]&!'!!]:M
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M1-*MY[#3%AN9+FWN)%,EOY!;>K$<9PN?QJC^S5^TKHG[3'@Z]U[PSI]WI?\
M9^H-9W%I=R*TB$ ,K_+V8'C\:+,#V&BJ6M:O:>'](O-3U:>.VLM/@>>XFD;"
MQQH"68GV -?*OP8_X*,>#OC-\5K'P1IOA_5M*FU.66.TO[NXC,4K("5  YRP
M'%%F!];T4BG(R1B@\"@!:*^'=8_X*G^&=+\2:IHT/P]\67USI-S-!*;:6-]W
MEN5+ #G'%>C_ +/G[?7@+X_^)SX;L[35/#FO2 FTM-3VXN\ E@C*2-P Z'!H
MLP/INBOGS6_VP]&T3]I6Q^#<WA_4Y-5OWB5-269/(7S(RX)7[W &*[#X\_M(
M>#?V=O#(U?Q_>,))P?L6GVV'N;QAU"(2.!W8X HLP/4Z*^*O"?\ P52^'.MZ
M_8V'B/P[XG\-6>H.%CU&\2-XD!Z,VTYV^I&<5]D:5K%IKFGV]]H]Q#>V=W&)
M(+B!PZ2(1D,K#J#18"[17S]\./VR/#/Q,^/OB#X6Z'IM\E[H(N =2>5##<M"
M0'5 .>"3U_NFMKQ#^U#X>\/_ +1.@?""2TN;C6M<LS<&\CE7RK5BK,L;@\[F
M5-PQV(HL![/17A/[4'[6&D_LNZ?H-WXBT+4M;77YY(8DLI40QE%#9.[L<UX<
M?^"J.B>7O3X6>/&!&00J8(QVXIV ^YZ*\$^/7[6NE? +X;^%O&&N^']4U&V\
M4-&L5K;RHDEN7B\WY]W' XX[UXA%_P %8O!\+0OK/P_\:6-I.1LN/W3!@>X!
M(S^=%@/NJBN ^#_QT\&?'7P[_;'PWUB#488\"XMS\D]JQ_ADC/*G]#V-=\#F
ME8!:***0!1110 4445: ****@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/2ORA_X*NRW=O\
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M\![M;W2R ?@<&MXYOA)?:/+K<$YY2WH-^C3_ %/J\N!U!_*@.#WKYUA_;7\
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M<$P.0Z:/ &'T.VNUHH AM[=;:,1Q(B(@ 54& !]!P/PJ:BBDP"BBBI ****
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M*8>E-&M/9@""3BEHHIFJ5D?H/^Q'_P D+MO^PK=_^ABBC]B/_DA=M_V%;O\
M]#%%??Y?_NM/T1_+_%/_ ".\5_CE^9[Y11172> %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10
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MBI_]NK_(^ ;S]BOXD0Y\E-"F'^S?;<_FM9+?LB_$Y/NZ/9/]-12OT2< ]:3
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IS^QDBQ_!2%8U55&JW?"C ^_17V^!5L-37DC^>N(Y^TS?$R[SE^9__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
